# **TAYSIDE PRESCRIBER**



# Tayside D&TC Supplement No. 30

Produced by Tayside New Medicines Implementation Panel (NMIP)

Sept 2003

## The Introduction of New Medicines in NHS Tayside

The Scottish Medicines Consortium (SMC) now provides advice to NHS Scotland on the use of all new medicines, major new formulations and new indications of existing medicines. The NHS Tayside Clinical Board has agreed that SMC recommendations should be adopted across Tayside. The **New Medicines Implementation Panel** (NMIP) has subsequently been established, as a sub-committee of the NHS Tayside Drug and Therapeutics Committee (D&TC), to facilitate the local implementation of SMC advice. The NMIP includes representation from clinicians in Tayside University Hospitals (TUH), Tayside Primary Care (TPC), Local Health-Care Co-operatives, NHS Tayside Board, and Tayside Medicines Unit.

## NMIP aims to:

- $\Rightarrow$  consider SMC advice in relation to local practice
- $\Rightarrow$  estimate the resource implications of implementing SMC advice across Tayside
- ⇒ liaise with Clinical Team Leaders (TUH) and Lead Clinicians (TPC) to develop local advice
- ⇒ disseminate local advice via the D&TC web-site and the Tayside Prescriber, D&TC Supplement
- $\Rightarrow$  design an educational programme in relation to new medicines

## The NMIP does not make decisions around the prioritisation or funding of new medicines.

## **The NMIP Process**



<sup>3</sup> NMIP Summary aims to facilitate Directorate submissions to the TUH new medicines contingency fund

The success of the above NMIP process will be evaluated one year after introduction.

## Funding of High Cost New Medicines

Considerable discussion has taken place locally around the funding of new medicines. The following points were agreed when prescribing budgets were set at the start of 2003-04:

- GP prescribing new medicines would be funded from the 2003-04 allocation uplift
- **GP prescribing** new medicines would be funded from a trust contingency
- **TUH prescribing** high cost new medicines would be funded from a trust contingency fund.

## **Accessing TUH Contingency Funds**

The following process has been agreed when a Directorate indicates that it is unable to absorb additional costs associated with the introduction of a new medicine



1 assuming bid approved

## Funding of Secondary Care New Medicines in TPC

Funding discussions are ongoing in TPC. Further details will be provided when available.

## How do prescribers know which drugs are recommended for use locally?

The Tayside Prescriber D&TC Supplement provides local advice on new medicines and is issued each month at the same time as the SMC issues national advice.

- If you are interested in prescribing a new medicine that has been launched since Jan 2002 but are unsure of its status, check the D&TC web-site (<u>www.show.scot.nhs.uk/thb/adtc</u>) under New Medicines and <u>NMIP Recommendations</u>.
  - If the medicine is listed, click on the relevant D&TC Supplement link to gain access to points for consideration put forward by NMIP.
  - If the medicine is not listed, it may be under evaluation. Information on which new medicines will be considered by the SMC over the next two to three months is available on the SMC website (<u>www.scottishmedicines.org.uk</u>) under "<u>Work Programme</u>".

#### In support of the national SMC process:

- New medicines should not be prescribed locally until they have been evaluated by the SMC and a recommendation for use has been made.
- When new medicines are not recommended for use by SMC they should not be prescribed in Tayside.

#### **Contact details:**

Local implementation of SMC recommendations is being taken forward by the Tayside Medicines Unit – contact Jan Jones, Pharmaceutical Prescribing Adviser (jan.jones@tpct.scot.nhs.uk) if you have any queries in relation to the introduction of new drugs within NHS Tayside